Adding immunotherapy after initial treatment can benefit metastatic lung cancer patients
by Perelman School of Medicine at the University of PennsylvaniaTreating metastatic non-small cell lung cancer (NSCLC) patients with the immunotherapy drug pembrolizumab after they've complet
Updated on: May 05,2024
19

Adding immunotherapy after initial treatment can benefit metastatic lung cancer patients
by Perelman School of Medicine at the University of PennsylvaniaTreating metastatic non-small cell lung cancer (NSCLC) patients with the immunotherapy drug pembrolizumab after they've complet
Updated on:May 05,2024
19
